The UK’s dual-track approach includes testing a next-generation mRNA vaccine. (Photo: Unsplash)
⚡ Quick Answer
A Moderna mRNA bird flu vaccine trial began in the UK in April 2026, testing a jab against H5N1 on poultry workers and over-65s. This is a clinical trial, not a public rollout. Separately, the UK government holds a strategic stockpile of more than 5 million doses of a traditional H5 vaccine from CSL Seqirus UK as pandemic insurance — not in deployment. UKHSA’s current risk assessment on human-to-human transmission is low. For most readers, no action is needed beyond ordinary hygiene and reporting dead wild birds.
Headlines about a bird flu vaccine in the UK have been doing the rounds this spring. In April 2026, ITV News reported that a Phase 3 trial of a Moderna mRNA vaccine against H5N1 had begun, backed by the National Institute for Health and Care Research (NIHR). The questions that followed were understandable: is a pandemic coming? Can I get a jab? This piece is the straight answer to both. It explains what’s actually happening in 2026, who the vaccine is for right now, who it isn’t for, and what a regular UK reader should and shouldn’t do.
What actually launched in April 2026 — the Moderna mRNA-1018 trial
In April 2026, a Phase 3 clinical trial for Moderna’s mRNA-1018 H5N1 vaccine formally opened to recruitment. This is a controlled research study, not a national vaccination campaign. The trial aims to enrol 4,000 adult volunteers worldwide, with around 3,000 of those (about 75%) to be recruited and vaccinated at 26 UK clinical sites spread across England and Scotland.
The trial is recruiting from two specific groups: people who work in the poultry industry and adults aged 65 and over. Participants receive two doses of the mRNA-1018 vaccine, spaced three weeks apart, and are then followed for a total of seven months so researchers can assess both its safety profile and its ability to trigger an immune response. Moderna is the sponsor of the trial, with the UK arm organised and supported through the NIHR’s Clinical Research Network.
The vaccine uses the mRNA platform — the same technology behind some of the Covid-19 vaccines. In plain terms, it gives the body a set of instructions to produce a harmless fragment of the H5N1 virus’s surface protein. The immune system picks that fragment up, learns to recognise it, and builds defences against it. If the real virus shows up later, the body is already primed to respond.
Why poultry workers and over-65s — the logic of the target groups
The two priority groups aren’t a random selection; they follow directly from risk assessment.
Poultry workers are, by a large margin, the people in the UK most likely to come into direct contact with birds carrying avian influenza viruses. Farms, processing sites, backyard poultry keepers — those are the points where any animal-to-human spillover would be first detected. Making that group the frontline for both surveillance and potential vaccination protection is logical whether or not a pandemic ever materialises.
Over-65s come into the trial for two separate reasons. One, older adults are reliably more vulnerable to severe complications from any kind of influenza. Two, the immune system becomes less responsive to vaccines with age — a phenomenon immunologists call immunosenescence. If a vaccine is going to work at all in the group that would most need protection, the trial has to demonstrate that early. Testing the vaccine in that population now gives researchers the data they’d need to decide, in a pandemic scenario, whether and how to deploy it at scale.
Poultry workers are the UK frontline for avian influenza surveillance and potential protection. (Photo: Unsplash)
The 5-million-dose stockpile — separate from the trial, insurance rather than rollout
Long before this trial opened, the UK government was making separate preparations. In late 2024, a contract was announced with CSL Seqirus UK Limited for more than 5 million doses of a human H5 influenza vaccine. It’s worth being clear that this stockpile is entirely separate from the Moderna trial. This is a traditional, egg-based influenza vaccine — well-established manufacturing technology, distinct from the mRNA approach Moderna is testing.
The purpose of the stockpile is strategic insurance. It’s designed to be available immediately if H5N1 mutates to transmit efficiently between humans, buying time while a pandemic-specific vaccine is produced at scale. As the GOV.UK press release from UKHSA put it, this is about “preparedness” — not deployment. None of those 5 million doses are being rolled out to the public. The UK’s approach mirrors what the US, EU, and Japan are doing: all four are stockpiling H5 vaccines as part of broader pandemic-preparedness plans covering multiple potential pathogens.
The dual-track approach — trial one vaccine, stockpile another — gives the UK both a potential next-generation tool (mRNA, rapidly reformulable if the strain shifts) and a proven, scalable fallback (egg-based, familiar manufacturing). In a pandemic, you’d want both.
UKHSA’s current risk assessment — why officials are NOT saying pandemic is imminent
🔬 UKHSA risk assessment
Current human-to-human risk: low
Per the UK Health Security Agency’s most recent assessments, the current risk of human-to-human H5N1 transmission remains low. UKHSA’s published line is that the current H5 viruses lack the properties to efficiently infect the upper respiratory tract of humans or to spread easily between people.
→ H5 lacks properties for efficient human transmission.
→ Widespread in birds + mammals globally, with concerning jumps to US dairy cattle.
→ Isolated UK poultry worker cases detected via asymptomatic surveillance.
How mRNA flu vaccines actually work — the technology in plain English
mRNA vaccines work by delivering instructions rather than the virus itself. For the H5N1 vaccine, the mRNA carries the code for a specific piece of the virus called hemagglutinin — the “H” in “H5N1”. Hemagglutinin sits on the surface of the influenza virus and is what it uses to latch onto and enter human cells. The vaccine tells your cells to build that protein, harmlessly, so the immune system can practice spotting it.
The practical advantage of the mRNA platform is speed. Traditional flu vaccines are grown in chicken eggs, which takes months and depends on the specific strain being cultivated. An mRNA vaccine can be reformulated for a new strain significantly faster — a matter of weeks rather than months if the platform itself is already approved. That’s why the UK’s two-platform approach is sensible rather than duplicative. The Moderna trial explores the rapid-response tool; the CSL Seqirus stockpile provides the proven, large-scale backup. In a real pandemic scenario, you’d want to be able to pull both levers.
What you should actually do as a regular UK reader
For the vast majority of people in the UK right now, no specific action on bird flu vaccination is needed or possible. There isn’t a public vaccination programme for H5N1, and the vaccines in the trial and the stockpile aren’t available to the general public.
A couple of specific things do apply, though. First, the seasonal flu jab offered by the NHS each autumn and winter does not cover H5N1. Seasonal vaccines target the human influenza A and B strains that circulate year-to-year in people, which are genetically different from H5N1. So getting the seasonal jab — still a good idea, particularly if you’re over 65 or in a clinical risk group — isn’t protection against bird flu. Second, if you keep backyard poultry or ducks, follow the biosecurity advice on the Department for Environment, Food & Rural Affairs (Defra) website. For everyone else, the most useful thing is to report any dead wild birds — especially multiple dead birds in the same area — to the Defra helpline on 03459 33 55 77. Don’t handle dead or visibly sick wild birds. If you work in the poultry industry and are interested in the trial, ask your occupational health team or check the NIHR “Be Part of Research” portal for eligibility and participating sites.
Five honest questions most people are asking — and honest answers
Frequently Asked Questions
⭐ The Bottom Line
Preparedness, not panic.
A vaccine trial and a stockpile are signs of a functioning preparedness system, not an imminent crisis. The UK’s approach is two-pronged: testing a next-generation mRNA vaccine on the people at highest occupational and age-related risk, and holding a traditional vaccine supply as insurance. Your role as a member of the public hasn’t changed. Stay sensibly informed through UKHSA. Practice normal hygiene. Report unusual wild-bird deaths. If you keep poultry, follow Defra biosecurity. Beyond that, there’s no vaccination action to take and no cause for alarm. The goal of public health preparedness is, quite deliberately, to be ready for something that may never arrive.
Related reading: GOV.UK avian influenza situation · NIHR trial announcement
Last updated: April 2026. This information is based on public statements from UKHSA, NIHR, and GOV.UK as of April 2026. It does not constitute medical advice.
